Federated Hermes
TRVI icon

Federated Hermes’s Trevi Therapeutics TRVI Stock Holding History

Federated Hermes’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-598
Closed -$2K – 2193
2024
Q3 		$2K Sell
598
-175
-23% -$520 ﹤0.01% 1939
2024
Q2 		$2.3K Hold
773
– – ﹤0.01% 1890
2024
Q1 		$2.67K Sell
773
-177
-19% -$395 ﹤0.01% 1893
2023
Q4 		$1.27K Buy
+950
New +$1.44K ﹤0.01% 1961
2022
Q4 		– Sell
-872
Closed -$1K – 2288
2022
Q3 		$1K Buy
+872
New +$2.86K ﹤0.01% 2084

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Federated Hermes's TRVI Position: Q4 2024 in Review

Federated Hermes sold out of Trevi Therapeutics (TRVI) in Q4 2024, closing a stake of 598 shares — an estimated $2K sold.

Federated Hermes first reported a position in TRVI in Q3 2022 and held it in 5 quarters. The position peaked at $2.67K in Q1 2024. 110 funds tracked by Wall St. Rank hold TRVI as of Q4 2024.

  • Federated Hermes reported no remaining Trevi Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Federated Hermes sold 598 Trevi Therapeutics shares in Q4 2024, an estimated $2K.
  • Federated Hermes first reported a position in Trevi Therapeutics in Q3 2022 and held it in 5 quarters.
  • Federated Hermes's Trevi Therapeutics position peaked at $2.67K in Q1 2024.
  • 110 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q4 2024.

Based on Federated Hermes's 13F filing for Q4 2024, filed 13 Feb 2025.